Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral islatravir monthly for HIV pre-exposure prophylaxis in MSM and transgender women
PACTR202109759050023Phase 3Unknown
- Sponsor
- MSD
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of islatravir and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by MSD. Status: unknown.
02
Drugs
islatraviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202109759050023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202109759050023.